Hinge Health Reports Strong Q1 Results, Raises Full-Year Outlook, and Executes Share Repurchase
Summary
Hinge Health reported robust Q1 2026 financial results, including 47% year-over-year revenue growth and a significant increase in profitability and cash flow, leading to a raised full-year revenue outlook and a notable reduction in share count through repurchases.
Key Events
-
Strong Q1 2026 Financial Performance
Revenue increased 47% year-over-year to $182.3 million. GAAP income from operations surged 144% to $32.1 million, and non-GAAP income from operations rose 208% to $46.2 million. Net cash provided by operating activities significantly improved to $43.1 million, up from $4.9 million in Q1 2025.
-
Raised Full-Year 2026 Revenue Outlook
The company increased its full-year 2026 revenue guidance by approximately $64 million at the midpoint, now expecting between $798 million and $804 million, reflecting 36% year-over-year growth at the midpoint.
-
Significant Share Repurchase Activity
Hinge Health reduced its diluted weighted average share count by 2.5% from Q4 2025, indicating the execution of its share repurchase program with over $100 million used for repurchase and retirement of common stock.
-
Healthy Balance Sheet and Cash Flow
The company reported $407.1 million in cash, cash equivalents, marketable securities, and restricted cash as of March 31, 2026, alongside a substantial increase in free cash flow to $41.6 million.
Analysis
Hinge Health delivered exceptional first-quarter results, significantly exceeding expectations across revenue, profitability, and cash flow. The substantial increase in full-year revenue guidance demonstrates strong management confidence in continued growth. Furthermore, the company's active execution of its share repurchase program, reducing the diluted share count, signals a commitment to returning value to shareholders and reflects a positive outlook on its valuation. This combination of strong operational performance, improved outlook, and shareholder-friendly capital allocation makes the filing highly impactful for investors.
At the time of this filing, HNGE was trading at $54.03 on NYSE in the Technology sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $30.08 to $62.18. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.